However, in PD-L1-positive HCC models, the cytotoxic efficacy of GPC3-CAR-T cells is significantly reduced, though combining PD-1 inhibitors significantly enhanced their antitumor activities[124]. This evidence concerns the gene GPC3 and hepatocellular carcinoma.